c58c72c3-3152-461a-b55a-9bcccc0b71f4
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 48
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.680
- G2M_CHECKPOINT+0.630
- MYC_TARGETS_V1+0.560
- MYC_TARGETS_V2+0.500
- PANCREAS_BETA_CELLS+0.430
- MITOTIC_SPINDLE+0.390
- UNFOLDED_PROTEIN_RESPONSE+0.390
- MTORC1_SIGNALING+0.350
- DNA_REPAIR+0.280
- SPERMATOGENESIS+0.220
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.350
- INTERFERON_GAMMA_RESPONSE-0.330
- MYOGENESIS-0.310
- COAGULATION-0.290
- ALLOGRAFT_REJECTION-0.250
- BILE_ACID_METABOLISM-0.240
- CHOLESTEROL_HOMEOSTASIS-0.230
- ANGIOGENESIS-0.210
- XENOBIOTIC_METABOLISM-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DK-A3IM-01A-11R-A20F-07 | — | — | 0.855 |
| 2 | BS_A0DYVX9J | high-grade glioma | — | 0.821 |
| 3 | de5a4588-05ec-461f-9235-90611b01f4b6 | — | — | 0.821 |
| 4 | SRR8518152 | — | E | 0.807 |
| 5 | BS_8QB4S4VA | Embryonal tumors | — | 0.804 |
| 6 | SRR33532819 | — | E | 0.799 |
| 7 | SRR25043634 | — | — | 0.798 |
| 8 | SJEPD030795_D3.RNA-Seq | EPN | Posterior Fossa EPN | 0.791 |
| 9 | TCGA-D6-6823-01A-11R-1915-07 | — | — | 0.791 |
| 10 | MDT-AP-0540 | Med | Medulloblastoma | 0.790 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.680 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.630 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.560 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.430 | Cobimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.390 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.390 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.280 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.170 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.160 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.150 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.050 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.040 | Inavolisib | — uncovered |
| HYPOXIA | 0.020 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.010 | Inavolisib | — uncovered |